Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 30Carcinoma, Hepatocellular 13Rectal Neoplasms 5Sarcoma, Ewing 4Osteosarcoma 4Gastrointestinal Stromal Tumors 4Colonic Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasm Metastasis 3Glioblastoma 3Sarcoma 2Neoplasms 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Esophageal Neoplasms 2Chondrosarcoma 2Bone Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Solid Malignant Tumors 1Small Cell Lung Carcinoma 1Recurrence 1Piebaldism 1Patient Compliance 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Malignant Tumors × regorafenib × 1 year × Clear all
NCT06246643 2026-05-19

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

Bayer

Phase 2 Active not recruiting
13 enrolled

Solid Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡